Other languages Shandong Boan Biotechnology Co., Ltd.

Equities

6955

CNE100005RV4

Delayed Hong Kong S.E. Other stock markets 03:31:22 06/06/2024 BST			5-day change	1st Jan Change
9.25 ^HKD	-1.39%		-1.29%	-40.65%

05-28	China Accepts Boan Biotechnology's Biologics License Application for Type 2 Diabetes Drug	MT
05-27	Shandong Boan Biotechnology Co., Ltd. Announces Acceptance of BLA in China for Dulaglutide Injection	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

China Accepts Boan Biotechnology's Biologics License Application for Type 2 Diabetes Drug	05-28
Shandong Boan Biotechnology Co., Ltd. Announces Acceptance of BLA in China for Dulaglutide Injection	05-27
Shandong Boan Biotechnology GCTB Drug NMPA's Marketing Approval	05-27
Shandong Boan Biotechnology Co., Ltd. Announces Approval of Denosumab Injection by the National Medical Products Administration	05-27
Shandong Boan Biotechnology Completes Phase 3 Trial for Retina Injection	04-08
Shandong Boan Biotechnology Co., Ltd. Completes Phase 3 Clinical Trial in China for Aflibercept Intravitreous Injection and Plans to Submit Biologics License Application	04-08
Ocumension Therapeutics' Eye Drug Completes Clinical Trials, to Apply for NDA Soon	04-08
Shandong Boan Biotechnology Trims Attributable Loss in 2023	03-26
Shandong Boan Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	03-25
Shandong Boan Biotech Completes Phase 3 Trial for Type 2 Diabetes Injection; Shares Surge 10%	03-08
Shandong Boan Biotechnology Co., Ltd. Announces Phase 3 Clinical Trial Completed in China for Dulaglutide Injection	03-08
Shandong Boan Biotechnology Authorizes CDMO Service Provider to Use Stable Cell Line Development Platform	01-30
Shandong Boan Biotechnology Co., Ltd. Enters into Agreement with the Zencore Biologics Co., Ltd	01-30
Boan Biotechnology, Joincare Sign Exclusive License Deal for Respiratory Disease Treatment	01-29
Shandong Boan Biotechnology Co., Ltd. Announces Orphan Drug Designations for Treatment of Gastric Cancer by FDA	01-24
Shandong Boan Biotechnology Co., Ltd. Obtains GMP Certification for Boyuno®? from the Brazilian Agencia Nacional De Vigilancia Sanitaria	01-17
Boan Biotech Completes Enrollment for International Multicenter Comparative Clinical (Phase 3) Study of Its Denosumab	01-12
Shandong Boan Biotechnology Co., Ltd. Announces Resignation of Chen Jie as Non-Executive Director	12-12
Boan Biotech Announces First Patient Enrolled in Phase III Clinical Trial of Boan Biotech's Nivolumab Injection	30/10/23
Shandong Boan Biotechnology's H1 Attributable Loss Narrows; Shares Fall 7%	22/09/23

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Shandong Boan Biotechnology Co., Ltd.

Equities

6955

CNE100005RV4

Other languages

Filters